Archive for January 2023
Hadassah Medical Organization and Bar-Ilan University Collaborate with Immix BioPharma for the Further Development and Commercialization of Next-Generation CAR-T Therapy
HBI0101, anti-BCMA CAR-T cells, showed 90% overall response rate in ongoing Phase 1b clinical trial with 50 relapsed/refractory multiple myeloma patients HBI0101 also demonstrated 100% overall response rate in 6 relapsed/refractory AL Amyloidosis patients Jerusalem & Ramat Gan, Israel – January 4, 2023 – Hadasit, the Innovation Engine of Hadassah Medical Organization and BIRAD, the…
Read More